KURA | Ticker Profile - Titan Protect

KURA

Kura Oncology, Inc.

Healthcare · Biotechnology · NMS

$8.74

Data: 2026-05-28

✓ ETHICAL PASS

Unknown MOAT

HIGH

Data Confidence: 85.7%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$909M

Total market value of the company

Trailing P/E

N/A

Forward P/E

-4.01

Based on estimated future earnings — lower means cheaper

Rev Growth

+29.5%

Year-over-year revenue change

Profit Margin

0.0%

How much profit the company keeps from each dollar of revenue

ROE

-124.7%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$28.00

+220% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 12 analysts covering this stock

About Kura Oncology, Inc.

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.

https://kuraoncology.com

Country: United States Employees: 260 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

0.0% N/A

Interest-bearing cash below 33% of assets

Receivables

0.0% N/A

Receivables below 49% of assets

Revenue Purity

0.0% PASS

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKUP

Price trending up with increasing momentum

Sharpe Ratio

-0.280

Returns do not compensate for the risk — negative edge

Kelly Fraction

-0.0425

No positive edge detected — the data suggests staying out

Calmar Ratio

-0.399

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-30.4%

Historical annualised return based on price data

Max Drawdown

-76.2%

Largest peak-to-trough decline — the worst it has been

HMM State

SIDEWAYS

Price consolidating — no clear directional bias

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

0.32

Very low correlation to market moves

52W High

$12.49

30% below the year high

52W Low

$5.45

60% above the year low

Avg Volume

1,601,586

Average daily shares traded — higher means easier to buy and sell

Short Ratio

11.7

Days it would take all short sellers to cover — higher means more crowded

Short % Float

18.1%

Elevated short interest — bears are positioned against this

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-3.35

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

22.50

Heavy leverage — higher financial risk if revenues decline

Current Ratio

6.15

Strong balance sheet — comfortably covers short-term obligations

Quick Ratio

5.86

Like current ratio but excludes inventory — stricter test

Gross Margin

-263.9%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-431.5%

Profit from core operations before interest and tax

Free Cash Flow

$-129,832,496

Negative — the business is spending more than it generates

Revenue (TTM)

$72M

Total revenue over the last 12 months

Net Income

$-294,569,984

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$76.00

Target Median

$28.00

Target Low

$15.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go